When do the MANNITOL 5% IN PLASTIC CONTAINER patents expire, and when will MANNITOL 5% IN PLASTIC CONTAINER go generic?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
B Braun	MANNITOL 5% IN PLASTIC CONTAINER	mannitol	INJECTABLE;INJECTION	020006-001	Jul 26, 1993	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Otsuka Icu Medcl	MANNITOL 5% IN PLASTIC CONTAINER	mannitol	INJECTABLE;INJECTION	019603-001	Jan 8, 1987		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: April 24, 2026

Mannitol 5% in plastic container is a mature, low-complexity infusion product with pricing driven by hospital formularies, tender economics, and regulatory supply continuity. For investors and R&D sponsors, the value case concentrates on manufacturing scale, supply reliability, and cost competitiveness rather than platform IP creation. The dominant “fundamentals” are supply-chain execution (polymer compatibility, container integrity, sterile filling) and procurement access (group purchasing organizations, national tenders, and distributor channels).

What product is “MANNITOL 5% IN PLASTIC CONTAINER” in commercial terms?

Mannitol injection 5% is an isotonic/near-isotonic osmotic agent used intravenously for indications such as cerebral edema and increased intracranial pressure, intraocular pressure reduction, and as an adjunct in certain clinical settings (use depends on jurisdiction labeling). The “plastic container” designation typically refers to ready-to-administer IV bags (commonly flexible plastic containers used for large-volume parenterals).

Commercially, this sits in the large-volume parenterals (LVP) category, where:

Formulations are generally simple and widely standardized.
Regulatory differentiation often comes from container system qualification, stability/compatibility data, and manufacturing controls.
Competitive entry is mostly about demonstrating equivalence and maintaining consistent supply.

Economic implication: For most geographies, this product competes on unit cost, service levels, and tender awards, not on patent exclusivity.

Is there meaningful patent leverage or exclusivity for this specific product?

“Man nitol 5% injection in plastic container” is generally treated as a long-established drug product. In practice, market exclusivity for LVPs like mannitol usually relies on:

Legacy patents (often expired for older drug substances and basic formulations), and/or
Process and container-system patents that may or may not still be active, depending on manufacturer and geography.

For an investor, the key reality is that the label “mannitol 5% injection” by itself does not signal a modern, defensible IP position. The most investable differentiators are operational:

Container-system competence (leachables/extractables qualification, seal integrity)
Aseptic filling yield and sterility assurance
Supply capacity and tender execution

If you are underwriting equity or debt tied to this product, treat it as a manufacturing and distribution play unless a specific active patent portfolio is identified for a particular manufacturer/container system in target jurisdictions.

How do fundamentals map to price, margin, and volume?

Demand drivers (volume stability)

LVPs are hospital consumables with relatively predictable demand:

Mannitol is used across acute care settings and perioperative pathways.
Hospital usage patterns are influenced by clinical protocols, but substitution is limited by clinician trust and procurement rules.

Pricing drivers (margin pressure)

Pricing is usually determined through:

Tender-based purchasing
Portfolio bundling (distributors negotiate baskets across multiple LVPs)
Competitive generic entry

Typical business model outcomes

For investors, this product category tends to deliver:

Stable volume where supply is reliable
Compressing margins in competitive geographies
Margin upside only when a supplier wins on cost structure, logistics, or service

Where does “plastic container” change the risk-return profile?

The container system matters because LVP performance depends on material compatibility:

Mannitol must remain stable in the solution under shelf-life conditions.
Container material and closure system must prevent unacceptable leachables/extractables.
Sterility and physical integrity must hold through distribution and handling.

Investment implication: Plastic-container qualification raises technical barriers versus generic “same API, different supplier,” but not to the level of a patented platform. It creates a recurring capability requirement:

Documentation and ongoing validation
Supplier qualification for container film and closures
Batch-to-batch consistency and quality controls

This shifts the fundamentals toward operational readiness.

What regulatory pathway and compliance burden should be assumed?

This product is typically regulated as a sterile injectable under national rules for drug manufacture and distribution. Core compliance categories include:

Sterile manufacture and aseptic processing controls
Container-closure integrity and stability programs
Labeling and import/manufacturing authorization
Pharmacovigilance obligations

Business impact: Regulatory compliance tends to be “table stakes” for entrants after initial approvals. Ongoing compliance affects cost of goods and downtime risk (deviations, recalls, or batch rejections).

Investment scenario: base case, downside, and upside

Base case (most likely for new supply or incremental capacity)

Volume: steady, tied to tenders and hospital formularies
Pricing: competitive, driven by procurement cycles
Margins: moderate, dependent on yield, waste, and logistics costs
Risk: limited, unless a supply disruption occurs

Underwriting focus: unit economics (yield and waste), freight and temperature controls, and tender win-rate.

Downside case (margin squeeze and supply shocks)

Pricing compression: additional competitors bid lower in tenders
Cost inflation: container material or raw mannitol input costs rise
Manufacturing setbacks: sterility assurance issues increase batch holds and rejects
Service risk: if supply falls short, contracts shift to alternate suppliers

Underwriting focus: downside protection through multi-site production, safety-stock policies, and quality resilience.

Upside case (service-led wins and operational excellence)

Tender awards: supplier wins due to reliability and consistent fill quality
Manufacturing efficiency: higher yield and lower batch rejects
Portfolio effects: bundling with other LVPs improves distributor access and hospital contracts

Underwriting focus: capacity flexibility and commercial coverage in target regions.

Competitive landscape: what typically wins in LVP tenders?

In many markets, the supplier who wins tends to combine:

Lowest landed cost subject to compliance
Contractual reliability
Consistent availability (no backorders)
Packaging compatibility with hospital administration workflows

For mannitol 5% in plastic containers, differentiation is rarely clinical; it is commercial and operational.

Key operational and quality metrics that govern financial outcomes

Underwrite around measurable production and quality controls:

Manufacturing performance

Aseptic process yield and batch release rate
Mean batch rejection rate and OOS frequency
Fill accuracy and volume compliance
Waste rate from container defects or sterility failures

Quality system durability

CAPA cycle times for deviations
Trend performance of sterility and bioburden results
Stability program outcomes (assay, particulate, and appearance)
Container integrity outcomes under simulated distribution

Supply chain execution

Container logistics reliability (film/closure damage rates)
Lead time variability
Allocation performance during supply constraints

What are the main cost drivers in goods sold?

For LVPs like mannitol 5%:

API and excipients are only one component; packaging and sterile manufacturing overhead often dominate.
Plastic container procurement and qualification costs matter.
Aseptic processing time, labor, and batch monitoring drive fixed and variable costs.

Investment implication: Even if raw material costs are favorable, margins depend on container economics and production yield.

Valuation framework for an investment tied to this product

A practical approach is to model it as a cash-generating consumable with:

Tender-driven volume forecasts
Margin sensitivity to bid price and yield
Risk discount for supply and compliance events

Scenario model structure (inputs)

Forecast volume by geography and customer segment
Expected realized price (tender average less distribution costs)
Unit cost of goods (API + container + manufacturing + QC)
Manufacturing utilization (capacity utilization changes fixed absorption)
Quality and regulatory costs (ongoing compliance plus expected deviations)

Multiples

LVP-focused business lines often trade on:

Stability of contracted volume
Scale and cost leadership
Low incidence of recalls and serious quality events

Business development implications: where to target for traction

Because clinical differentiation is limited, commercial leverage comes from:

Hospital group tenders
Pharmacy procurement networks
Distributor relationships that manage LVP baskets
Contracts that specify plastic container form factor

Winning tends to require:

Contract readiness and pre-positioned supply
Documentation completeness
Consistent container lot traceability

Key Takeaways

Mannitol 5% in plastic container is a mature LVP category where competitive advantage is mainly operational: cost, yield, container compatibility, and consistent supply.
Patent leverage is typically limited at the product-description level; investment underwriting should prioritize manufacturing capability and tender access rather than expecting exclusivity economics.
“Plastic container” is a real technical barrier that raises qualification and quality-system requirements, but it is not usually a long-term patent moat.
Financial outcomes hinge on unit cost (container and aseptic yield), realized tender price, and service reliability during supply cycles.
Treat the investment case as a manufacturing and procurement execution thesis with downside protection around quality risk and supply continuity.

FAQs

1) What determines market share for mannitol 5% injection?

Tender awards and formulary inclusion dominate, with supplier reliability and consistent packaging (plastic container form factor) as key differentiators.

2) What is the biggest driver of margin for LVPs?

Aseptic manufacturing yield, batch release performance, and container economics usually outweigh small differences in API pricing.

3) Does “plastic container” create a durable competitive advantage?

It creates a qualification and quality capability barrier, but it is typically not a patent-style moat unless tied to active container-system intellectual property in specific jurisdictions.

4) What is the main risk profile?

Supply interruption and manufacturing quality events (batch holds, sterility failures, container integrity issues) are the primary downside risks impacting contracts and cash flow.

5) How should an investor value exposure to this product?

Use tender-based volume and price forecasts, model unit cost sensitivity to yield and container costs, and discount for quality and compliance event risk.

References

[1] U.S. Food and Drug Administration. Guidance for Industry: Preparation of Premarket Submissions for Management of Human Cells, Tissues, and Cellular and Tissue-Based Products (as applicable regulatory framework context). FDA. https://www.fda.gov/regulatory-information/search-fda-guidance-documents
[2] World Health Organization. Annex 6. Guidelines on the stability of vaccine products (general principles relevant to stability programs for sterile products). WHO. https://www.who.int/publications
[3] European Medicines Agency. Guideline on the quality of medicinal products containing antibiotics (sterile and quality system principles relevant to injectable compliance context). EMA. https://www.ema.europa.eu/en/guidelines
[4] International Council for Harmonisation. ICH Q8/Q9/Q10 (quality risk management and pharmaceutical quality system principles). ICH. https://ich.org/guidelines
[5] U.S. Pharmacopeia (USP). General Chapters on injections and sterility/particulates (container-closure and sterility requirements principles). USP. https://www.uspnf.com/

MANNITOL 5% IN PLASTIC CONTAINER Drug Patent Profile

When do Mannitol 5% In Plastic Container patents expire, and what generic alternatives are available?

AI Deep Research

Questions you can ask:

Summary for MANNITOL 5% IN PLASTIC CONTAINER

US Patents and Regulatory Information for MANNITOL 5% IN PLASTIC CONTAINER

MANNITOL 5% IN PLASTIC CONTAINER: Investment Scenario and Fundamentals Analysis